In January 2023, the US company announced top-line results of the company's completed Phase IIa clinical trial evaluating the safety and efficacy of its investigational bladder disorder treatment LP-10 for hemorrhagic cystitis, a rare but highly morbid disease for which there are currently no FDA approved treatments.